Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

550
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
550
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

413
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
413
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

434
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
434
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

443
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
443
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

384
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
384
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

263
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
263

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling SLE Treatment Cost-Effectiveness Based on a Novel LLDAS Treat-to-Target Approach.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Development and validation of EULAR quality indicators for lupus nephritis: adherence trends and impact on clinical outcomes.

Annals of the rheumatic diseases·2026
Same author

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study.

The Australasian journal of dermatology·2026
Same author

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

RMD open·2026
Same author

Clinical and autoantibody associations with malignancy in systemic sclerosis: A systematic review and meta-analysis.

Rheumatology (Oxford, England)·2026
Same author

Incidence of malignancy in systemic sclerosis: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2026

Related Experiment Video

Updated: Sep 28, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.3K

Small intestinal bacterial overgrowth in systemic sclerosis.

Kathleen Morrisroe1,2, Murray Baron3, Tracy Frech4

  • 1Department of Medicine, The University of Melbourne at St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.

Journal of Scleroderma and Related Disorders
|April 6, 2022
PubMed
Summary

Systemic sclerosis patients often experience small intestinal bacterial overgrowth, causing digestive issues. Early diagnosis and antibiotic treatment can significantly improve symptoms and prevent malnutrition.

Keywords:
Systemic sclerosispatient-reported outcome measuressclerodermasmall bowel bacterial overgrowthsmall intestinal bacterial overgrowth

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

67.7K

Related Experiment Videos

Last Updated: Sep 28, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.3K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.3K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

67.7K

Area of Science:

  • Rheumatology
  • Gastroenterology
  • Autoimmune Diseases

Background:

  • Systemic sclerosis (SSc) is a severe autoimmune disease affecting multiple organs.
  • Gastrointestinal (GI) involvement is highly prevalent in SSc (up to 90%), leading to significant morbidity and mortality.
  • Small intestinal bacterial overgrowth (SIBO) is a common and treatable GI manifestation in SSc.

Purpose of the Study:

  • To highlight the prevalence, symptoms, and diagnostic challenges of SIBO in SSc patients.
  • To discuss the impact of SIBO on SSc patient health and quality of life.
  • To emphasize the importance of early recognition and management of SIBO in SSc.

Main Methods:

  • Clinical symptom assessment for SIBO in SSc.
  • Diagnosis via hydrogen breath tests.
  • Treatment response evaluation with sequential oral antibiotics.

Main Results:

  • SIBO affects approximately 39% of SSc patients.
  • Common symptoms include diarrhea, bloating, abdominal pain, and early satiety.
  • Two-thirds of SSc patients with SIBO show symptom improvement with rotating antibiotics.

Conclusions:

  • SIBO is an understudied but significant complication in systemic sclerosis.
  • Early diagnosis and treatment of SIBO can ameliorate GI symptoms and prevent malnutrition.
  • Addressing SIBO is crucial for managing SSc patients, despite diagnostic and therapeutic challenges.